Nebenwirkungen · Usgena
Usgena 130 mg concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 8
HOS-153944 · Präparat HOS-101078
The safety data described below reflect exposure in adults to ustekinumab in 14 phase 2 and phase 3 studies in 6,710 patients (4,135 with psoriasis and/or psoriatic arthritis, 1,749 with Crohn’s disease and 826 patients with ulcerative colitis). This includes exposure to ustekinumab in the controlled and non-controlled periods of the clinical studies in patients with psoriasis, psoriatic arthritis, Crohn’s disease or ulcerative colitis for at least 6 months (4,577 patients) or at least 1 year (3,648 patients). 2,194 patients with psoriasis, Crohn’s disease or ulcerative colitis were exposed for at least 4 years while 1,148 patients with psoriasis or Crohn’s disease were exposed for at least 5 years.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-11T11:11:01Z · SHA-256 8e5be544de91a74438b6084c7497550446fa3104ba8f5e5368034aaef5a300fc · Passage 6f282dbe204cc98a87683c92ef6cc125f9ef82d0dd935e72fe8aaea1d12a530e · Zeichen 716–1424 im Abschnitt